Stockreport

Abeona Therapeutics: Maintaining 'Buy' On ZEVASKYN Launch Potential For RDEB [Seeking Alpha]

Abeona Therapeutics Inc.  (ABEO) 
Last abeona therapeutics inc. earnings: 3/16 04:20 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.abeonatherapeutics.com
PDF ZEVASKYN is the first autologous cell sheet-based gene therapy for RDEB, with FDA approval and broad payer access, targeting a $4B cumulative revenue opportunity. Pro [Read more]